NCT00035945已完成2 期
ISIS 14803-CS2, Treatment With ISIS 14803, Administered IV in Patients With Chronic Hepatitis C Virus Infections
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 试验地点
- 2
研究概览
简要总结
Purpose of this study is to evaluate the safety, tolerability, antiviral activity, and pharmacokinetic behavior of ISIS 14803 administered for up to 12 weeks by intravenous infusions in patients with chronic hepatitis C.
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- •Patients with any of the following criteria during screening will not be eligible:
- •Human immunodeficiency virus (HIV) infection (Western immunoblot confirmed presence of anti-HIV antibodies or detection of HIV RNA in blood).
- •Chronic hepatitis B virus (HBV) infection (HBV surface antigen or DNA in blood).
- •Antiviral therapy for HCV within 3 months.
- •Immunomodulatory therapy (e.g., systemic corticosteriods or interferon) within 3 months.
- •Advanced or decompensated liver disease (e.g., history of bleeding varices, spontaneous hepatic encephalopathy, ascites) of any etiology such as alcohol, drug, obesity, or hemochromatosis.
- •ALT greater than 5x ULN.
- •Histologic evidence of cirrhosis.
- •Presence of an underlying disease state associated with active bleeding.
- •Undergoing therapeutic anticoagulation with heparin or warfarin.
- •Presence of any other active infection requiring therapy.
- •Presence of malignancy.
- •Presence or history of any significant medical illness that might interfere with this study.
- •Receipt of an investigational new drug, biological or therapeutic device within 30 days of study entry.
- •Alcohol or drug abuse requiring medical intervention within 2 years.
- •History of non-compliance with prescribed medical care.
- •Limited mental capacity or language skills to the extent simple instructions cannot be followed or information regarding adverse events cannot be provided
研究者
研究点 (2)
Loading locations...
相似试验
已完成
1 期
Addition of ISIS 14803 to Therapy With Peginterferon and Ribavirin for Chronic Hepatitis C (HCV) Patients Not Responding Adequately to the Two DrugsHepatitis C, ChronicNCT00062816Ionis Pharmaceuticals, Inc.22
撤回
2 期
Safety, Tolerability, and Activity of ISIS 113715 in People With Type 2 Diabetes Mellitus Being Treated With SulfonylureaType 2 Diabetes MellitusNCT00327626Ionis Pharmaceuticals, Inc.
已完成
2 期
Safety, Tolerability, and Activity of ISIS 113715 in People With Type 2 Diabetes Mellitus Who Have Not Received Prior TreatmentType 2 Diabetes MellitusNCT00330330Ionis Pharmaceuticals, Inc.96
已完成
2 期
A Study of ISIS 416858 Administered Subcutaneously to Participants With End-Stage Renal Disease (ESRD) on HemodialysisEnd-stage Renal Disease (ESRD)NCT03358030Ionis Pharmaceuticals, Inc.213
已完成
2 期
Study of ISIS 301012 (Mipomersen) in Heterozygous Familial Hypercholesterolemia Subjects on Lipid Lowering TherapyHypercholesterolemia, FamilialNCT00281008Kastle Therapeutics, LLC44